Mechanisms of neuroregulation of corneal angiogenesis - the angiogenic privilege of the cornea refers to its normal avascularity, and loss of such privilege leads to pathological angiogenesis and…

Active Grant Awarded

Award ID
R01EY038179
Recipient
Awarding agency
Obligated
$654,589

Award facts

Assistance listing
93.867 Vision Research
Completion date 4% complete
Place of performance
Boston, MA 02114, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health National Eye Institute awarded Tufts Medical Center Parent, Inc., doing business as Tufts Medical Center, a grant under the Vision Research program (CFDA 93.867) on September 17, 2026, with $654,589 obligated under Grant R01EY038179. The award funds research into how sensory nerves maintain corneal angiogenic privilege and how their degeneration promotes pathological angiogenesis. The work uses an ex vivo co-culture of vascular endothelial cells and sensory neurons and an in vivo transgenic mouse model of corneal nerve degeneration. Aim 1 compares the angiogenic response in normal versus neurotrophic corneas. Aim 2 examines the role of neuropeptide alpha-melanocyte-stimulating hormone and its melanocortin receptor 1 in suppressing angiogenesis and tests therapeutic activation of their signaling in neurotrophic corneas. Aim 3 profiles immune cell populations in neurotrophic corneas, assesses their interaction with sensory neurons, and determines their roles in inflammatory angiogenesis through selective depletion of myeloid immune cells.

The period of performance runs from the September 17, 2026 award date to an ultimate completion date of June 30, 2031. Work is performed in Boston, Massachusetts, 02114.

Description

Mechanisms of neuroregulation of corneal angiogenesis - the angiogenic privilege of the cornea refers to its normal avascularity, and loss of such privilege leads to pathological angiogenesis and subsequent corneal opacity, decreased vision, and higher risks of transplant failure. The cornea is abundantly innervated by sensory nerves derived from the trigeminal ganglion. Degeneration of these nerves leads to neurotropic corneas at risk for persistent epithelial defect, ulceration and even perforation. Our preliminary data revealed that sensory neurons suppress vascular endothelial cell activation and that neurotrophic corneas have heightened angiogenic and inflammatory responses. This proposal aims to determine how sensory nerves maintain corneal angiogenic privilege and how their degeneration promotes pathological angiogenesis. We will utilize an EX vivo CO-culture system of vascular endothelial cells and sensory neurons and an in vivo transgenic mouse model with corneal nerve degeneration to study the following three specific aims. Aim 1 investigates the angiogenic response in normal versus neurotrophic corneas by comparing the effects of normal and degenerative sensory nerves on vascular endothelial cell activities in vitro and corneal angiogenesis in vivo. Aim 2 focuses on the role of neuropeptide alpha-melanocyte-stimulating hormone and its melanocortin receptor 1 in suppressing angiogenesis and examines the therapeutic effect of activating their signaling in treating angiogenesis in neurotrophic corneas. Aim 3 examines immune cell contributions to the neuroregulation of corneal angiogenesis by profiling immune cell population in neurotrophic corneas, assessing their interaction with sensory neurons, and determining their roles in mediating inflammatory angiogenesis in neurotrophic corneas by selective depletion of myeloid immune cells. In summary, this proposal investigates the direct inhibition of corneal angiogenesis by sensory nerves with emphasis on the roles of vascular endothelial and immune cells, and further explores how dysfunction of these mechanisms in neurotrophic corneas leads to heightened vascular response. This is of high relevance in ocular and non-ocular diseases characterized by peripheral nerve degeneration. Successful completion of this project will not only fill in the knowledge GAP in the neuroregulation of corneal angiogenesis but may lead to the development of potential therapeutics for mitigating pathological angiogenesis and regenerating sensory nerves.

Quick answers

Who received award R01EY038179?

R01EY038179 was awarded to Tufts Medical Center Parent, Inc. by National Eye Institute (National Institutes of Health) on September 17, 2026.

How much is award R01EY038179 worth?

$654,589 has been obligated on R01EY038179.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award